Last reviewed 2026-06-02 · How we verify

MTx-COVAB36

Memo Therapeutics AG · Phase 1 active Small molecule ✓ Verified Jun 2026

MTx-COVAB36 is a Small molecule drug developed by Memo Therapeutics AG. It is currently in Phase 1 development.

MTx-COVAB36 is a small molecule being studied as a therapeutic and prophylactic treatment against COVID-19 in a Phase 1 clinical trial. The trial is assessing the safety and tolerability of MTx-COVAB36 compared to a placebo in individuals with SARS-CoV-2 infection.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MTx-COVAB36
Sponsor	Memo Therapeutics AG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MTx-COVAB36 CI brief — competitive landscape report
MTx-COVAB36 updates RSS · CI watch RSS
Memo Therapeutics AG portfolio CI

Frequently asked questions about MTx-COVAB36

What is MTx-COVAB36?

MTx-COVAB36 is a Small molecule drug developed by Memo Therapeutics AG.

Who makes MTx-COVAB36?

MTx-COVAB36 is developed by Memo Therapeutics AG (see full Memo Therapeutics AG pipeline at /company/memo-therapeutics-ag).

What development phase is MTx-COVAB36 in?

MTx-COVAB36 is in Phase 1.

Manufacturer: Memo Therapeutics AG — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing